O'Connor T P, Labandter H P, Hiles R W, Bodenham D C
Br J Plast Surg. 1978 Oct;31(4):317-22.
A preliminary analysis of a controlled trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma has been carried out. The length of follow-up varied from 5 years to 6 months. No obvious benefit from BCG immunotherapy has been found so far. On the other hand the treatment is painful with an appreciable morbidity. Skin tests for delayed hypersensitivity have shown no recognisable differences in patients treated with surgery and those who also had BCG, or in the pattern of responses in those who developed recurrences and those who did not. In view of these early findings trial entry has been closed.
对卡介苗免疫疗法作为原发性恶性黑色素瘤手术辅助治疗的对照试验进行了初步分析。随访时间从5年到6个月不等。到目前为止，尚未发现卡介苗免疫疗法有明显益处。另一方面，该治疗很痛苦，发病率相当高。迟发型超敏反应皮肤试验表明，接受手术治疗的患者与同时接受卡介苗治疗的患者之间，以及复发患者与未复发患者的反应模式之间，均未发现可识别的差异。鉴于这些早期发现，试验已停止入组。
